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tude of the effect of ramipril in women vs. men. 
Conclusions: ACE inhibition with ramipril is highly effective in high-risk women without HF 
and with preserved LVEF. 
Effect of Ramlprll In Women 
Placebo (n=1201) Ramipril (n=1279 RR (95% CI) p 
MI, stroke, CV death 179 (14.9%) 145 (11.3%) 0.76 (0.61-0.94) 0.01 
MI 113 (9.4%) 105 (8.2%) 0.87 (0.67-1.14) 0.3 
Stroke 58 (4.8%) 40 (3.1%) 0.61 (0.43-0.86) 0.004 
CV Death 139 (11.6%) 118 (9.2%) 0.79 (0.62-1.02) 0.06 
Revascularizations 173 (14.4%) 150 (11.7%) 0.81 (0.65-1.00) 0.05 
Heart Failure 136 (11.3%) 117 (9.2%) 0.81 (0.63-1.03) 0.08 
Worsening Angina 312 (26.0%) 275 (21.5%) 0.80 (0.68-0.94) 0.007 
New Diabetes 27 (4.7%) 16 (2.7%) 0.58 (0.31-1.08) 0.08 
1051-29 Effects of Vitamin E on Cardiovascular and 
Microvascular Outcomes in High-Risk Diabetic Patients 
Eva Lonn. Hertzel Gerstein, Janice Pogue, Qilong Yi, Byron J. Hoogwerf, Jacqueline 
Bosch, GUles Dagenais, Salim Yusuf, McMaster Universi~ Hamilton, Ontario, Canada. 
Background: Oxidative stress is an important mechanism of atherogenesis and 
microvascular damage in diabetes. Elevated protein kinase C (PKC) may also increase 
microvascular damage. Vitamin E is an antioxidant and decreases PKC activation. 
Methods: We evaluated natural source Vitamin E (RRR-alpha-tocopheryl acetate) 400 
IU/day vs. placebo in 3,654 high-risk persons with diabetes enrolled in the randomized 
controlled Heart Outcomes Prevention Evaluation (HOPE) trial. Median follow-up was 
4.5 years. Data on major clinical outcomes were collected. Glycated hemoglobin (HbAlc) 
and serum creatinine were measured at baseline and yearly thereafter. Urinary albumin 
excretion was measured at baseline, 1 year and study end. Participants with albumin/ 
creatinine ratio higher than 36 mg/mmol had 24 hour urine collections. Nephropathy was 
defined as 24-hour urinary albumin excretion of 300 mg or more or total protein excretion 
of 500 mg or more. 
Results: Baseline characteristics were well balanced. Patients' mean age was 65 years, 
3,572 had type 2 diabetes, 1,356 were women, 2,189 had known CAD, 244 had prior 
stroke, 678 peripheral arterial disease, 2,031 hypertension, 2,384 hypercholesterolemia. 
Major event rates (in %) were similar in the 2 groups (Table). Serial measurements of 
HbAlc, urinary albumin/creatinine ratio and serum creatinine were also similar in the 2 
groups. 
Conclusions: Vitamin E 400 IU/day has a neutral effect on CV outcomes and microvas- 
cular complications in high-risk diabetics, 
CV and Mlcrovasculsr Event Rates (in %) 
Placebo (n=1816) Vitamin E (n=1838) RR (95% CI) 
MI, Stroke and CV Death 17.2 17.7 1.03 (0.88-1.21) 
MI 11.5 11.5 1.01 (0.83-1.22) 
Stroke 4.6 5.6 1.21 (0.91-1.62) 
CV Death 8.0 7.7 0.97 (0.77-1.23) 
Total mortality 12.8 11.9 0.93 (0.77-1.12) 
Heart failure 4.2 4.6 1.11 (0.81-1.51) 
Revascularizations 15.3 15.2 0.99 (0.82-1.17) 
Overt Nephropathy 7.2 7.9 1.12 (0.88-1.44) 
New Microalbuminuria 37.5 35.3 0.91 (0.79-1.03) 
Retinal Laser Therapy 10.0 9.9 0.99 (0.81-1.22) 
1051-30 Pharmacodynamic Interactions Between Tadalafil and 
Nitrates 
Robert Kloner. Jeff Emmick, Alun Bedding, Dennis Humen, Eli Lilly and Company, Erl 
Wood Manor, United Kingdom. 
Background: Tadalafil is a selective PDE5 inhibitor under regulatory review for the treat- 
ment of erectile dysfunction. Because sildenafil, another PDE5 inhibitor, is contraindi- 
cated in men taking nitrates, studies were undertaken to examine potential interactions 
between tadalafil and nitrates. Methods: Two double-blind, randomized, 3-way cross- 
over studies were conducted in patients with stable angina to determine: 1) Study A - 
response to sublingual nitroglycerin (SL NG) administered 2 hours after tadalafil 5 or 10 
m 9 or placebo (n=51); and 2) Study B - response after tadalafil 5 or 10 mg or placebo 
administered during daily long-acting nitroglycerin (LA NG) therapy (n=45). Reeulls: The 
table shows the results for the primary endpoint, which was mean maximal change in 
standing systolic BP (MMCSBP). 
Comparative Analysis of Standing MMCSBP Between Treatment Groups (mmHg) 
Tadalafil (10 mg)-Placebo Tadalafil (5 mg)-Placebo 
Mean Lower Bound of Mean Lower Bound of 
Difference 95% CI Difference 95% CI 
Study A (SL NG) -3 -6 -8* -12 
Study B (LA NG) -2 -6 0 -4 
*Mean difference statistically significant based on non-inferiority analysis 
Numbers of Patients with Standing SBP <85 mmHg (outliers) 
Placebo Tadalafil 5 mg Tadalafi110 m 9 
Study A (SL NG) 1 13 11 
Study B (LA NG) 0 0 6 
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There were no statistically significant differences in either study between tadalafil 5 or 10 
mg and placebo in the sitting position. Conclusions: Tadalafil had minimal effects, rela- 
tive to placebo, on mean blood pressure changes induced by either SL NG or LANG. 
However, the frequency of outliers was higher in the tadalafil treatment groups, indicating 
that in a subset of patients, tadalafil augments the decrease in BP induced by nitrates. 
These results suggest that, as with sildenafil, tadalafil should not be used in combination 
with nitrates. 
1051-45 Randomized Comparison of Exercise Training Versus 
PTCA/Stent in Stable Coronary Artery Disease: Effects 
on Clinical Status and Maximal Exercise Capacity 
Katrin Conradi, Sven M6bius-Winkler, Claudia Walther, Peter Sick, Jiangtao Yu, Kai 
Kenziorra, Regine Kluge, Rainer Hambrecht, Gerhard Schuler, University of Leipzig, 
Heart-Center, Department of Cardiology, Leipzig, Germany, University of Leipzig, 
Department of Nuclear Medicine, Leipzig, Germany. 
Introduction: In patients (pts) with stable coronary artery disease (CAD) regular exercise 
training has the therapeutic potential to improve physical work capacity (PWC). The aim 
of the present study was to evaluate the effects of exercise training in comparison to an 
interventional approach (PTCA and stent implantation) in pts with symptomatic CAD with 
respect to symptom-free PWC. 
Methods: 100 male pts with stable CAD (amenable for PTCA/stent implantation) were 
prospectively randomized to either a training (T, n=50) or an intervention group (INT, 
n=50). Pts of the training group exercised 20 minutes daily on a bicycle ergometer 
whereas pts in the intervention group received initially a PTCNstent implantation. At the 
beginning and after 6 months patients underwent a maximal symptom limited exercise 
stress test to assess PWC and maximal oxygen uptake (VO2 max). 
Results: After 6 months pts of both groups demonstrated a significant improvement in 
clinical status from 1.33±0.13 to 0.6±0.11 (CCS-class, p<0.01 vs. begin) in T and 
1.65±0.11 to 1.02±0.12 (p<0.01 vs. begin) in INT, respectively. Regular exercise training 
was associated with a significant increase in PWC (132=4.1 to 161±5 Watt; p<0.05 vs, 
INT) and peak oxygen uptake ( 22.2±0.6 to 25.3±0.9 mL./kgxmin, p<0.05 vs. INT) in T, 
whereas INT showed no difference (119=3,4 to 124±4 Watt, n.s.; 20.8±0.6 to 
21.5=0.7mL/kgxmin, n.s.) Twenty-six pts of T and fifteen of INT were completely free of 
clinical symptoms after 6 months 
Conclusions: These data suggest that in a selected daily physical exercise training 
seems to be a feasible alternative to an interventional approach with respect to clinical 
status and functional work capacity. 
1051-46 Assessment of Reperfusion Therapy on Regional and 
Global Left Ventricular Function in Patients With 
Chronic Total Coronary Artery Occlusions 
Cenaiz Ermis. AdU Boz, Venkat Tholakanahalli, Selim Yalcinkaya, Ender Semiz, Oktay 
Sancaktar, Leslie W. Miller, Necmi Deger, David G. Benditt, Cardiovascular Division, 
University of Minnesota, Minneapolis, Minnesota, Cardiovascular Division, University of 
Akdeniz, Antalya, Turkey. 
Background: The regional and global ventricular function benefit achieved by percutane- 
ous coronary intervention (PCI) with repertusion of the artery supplying the infarct area in 
acute myocardial infarction (AMI) is well described. In addition, several trials indicate that 
PCt in AMI, reduces morbidity and mortality. Conversely, although the survival benefit of 
PCI in the setting of chronic total coronary occlusion (CTO) has recently been shown to 
be of little value, little is known of the potential effects on regional and global left ventricu- 
lar function after late recanalization of CTO. This prospective study examined whether 
PCI improves regional and global left ventricular function (LVF) in CTO. 
Methods: Patients (pts) having at least one coronary artery occluded for >6 weeks dura- 
tion, were included in the study. Exercise TI-201 myocardial perfusion scintigraphy 
(TMS), multiple gated acquisition (MUGA) ventriculography, and 2-dimensional echocar- 
diography (Echo) were performed in each pt to assess both regional and global LVF 
before and 6 weeks after PCI. Paired sample t-tests were utilized for statistical analysis. 
Results: Thirty-five pts were enrolled in the study. Fifteen pts were subsequently 
excluded because of inability to open the artery and one because of emergent angio- 
plasty. In the remaining 19 pts (16 male and 3 female, mean age of 58=5 years) ejection 
fraction (EF) pre and post PCI, was 51±7% and 58±6% using Simpson's method 
(p<0.001) by Echo, and it was 45=1% and 53=1% (p<0.01) by MUGA, respectively. 
Echocardiographic wall motion score was 24±9 before and 15±6 (p<0.001) after PCI. 
Exercise perfusion score (21±1 and 14±1 [p=0.01]), rest perfusion score (15±1 and 12±1 
[p=0.02]), and re-injection perfusion score (14=1 and 11=1 [p =0.07]) all also improved. 
Conclusion: Percutaneous coronary reperfusion therapy significantly improved the 
regional and global left ventricular function in patients with chronic total coronary occlu- 
sion. Thus, although PCI may not benefit survival in CTO pts, improvement in ventricular 
function may provide important symptom benefits. 
1051-47 Nitric Oxide Activity in Complex Atheromatous Plaques 
Dimitris Tousoulis. Costas Tentolouris, Tom Crake, Costas Toutouzas, Athansios Trikas, 
Christos Pitsavos, Christodoulos Stetanadis, Graham Davies, Pavlos Toutouzas, 
Cardiology Unit, Hippokration Hospital, Athens University Medical School, Athens, 
Greece, Cardiology Unit, Hammersmith Hospital, London, United Kingdom. 
Background: Administration of L-arginine (LA) may stimulate the release of nitric oxide 
and improve myocardial ischemia.We sought to examine the effects of LA administration 
on coronary stenosis vasomotion in patients with coronary artery disease (CAD). 
Methods: Intracoronary infusions o1 normal saline, the receptor mediated nitric oxide 
stimulant LA (50 and 150 I~mol/min) and nitroglycerin (GNT) (250 mcg bolus) were 
administered in 15 patients with CAD and stable angina. Coronary stenoses were classi- 
fied as smooth (smooth with regular borders) or complicated (irregular borders). The 
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diameter of 12 smooth and 10 complex coronary stanoses and their adjacent reference ( 
R ) segment was measerad by quantitative angiography. 
Results: LA 50 ~mol/min dilated smooth stenoses (6.4+/-1.4%) and complex stenoses 
(7.3+/-3.2%). LA 150 I~mol/min significantly dilated smooth (7.3+/-2.9%) and complex 
stenoses (13.7+/-2.5%, p<0.05 vs smooth stanoses). No significant difference was found 
in R segment for smooth and complex stenoses in response to 50 pmol/min (4.5+/-1.4% 
and 6.3+/-2.9% respectively) and to 150 iJmol/min (10.5+/-2.2% vs 10.4+/-2.4%). GTN 
significantly dilated smooth (14.9+/-3.4%) and complex stanoses (19.4+/-2.3%). There 
was a significant correlation between stenosis severity and LA induced dilation (r=0.56, 
p<0.001). 
Conclusion: In patients with CAD, complex coronary stanoses dilate significantly more 
than smooth stanoses after LA administration. This finding is consistent with partial defi- 
ciency of the substrate for nitric oxide synthesis at the site of complex stenoses. The pro- 
vision of LA significantly enhances nitric oxide activity at the site of complex severe 
stenoses. 
1051-48 Selective Serotonin 5HT2A Receptor Inhibition 
Attenuates Myocardial lachemia Through the Increase 
in Nitric Oxide Production: The Alternative Role of 
5HTIB Receptor 
Shoii Sanada. Masafumi Kitakaze, Koichi Node, Hiroshi Asanuma, Hisekazu Ogita, Seiji 
Takashima, Masanori Asakura, Tetsuo Minamino, Masatsugu Hod, Osaka University 
Graduate School of Medicine, Suita, Japan, National Cardiovascular Center, Suita, 
Japan. 
Background: Serotonin is released during myocardial ischemia and activates both 
5HT1B/2B and 5HT2A receptors. The former activation increases nitric oxide (NO) produc- 
tion, and the latter constricts coronary artery. If 5HT2A receptors are blocked during myo- 
cardial ischemia, relative activation of 5HT1B/2 B receptors may enhance NO production 
and increase coronary blood flow (CBF). Therefore, we tested this idea using a selective 
serotonin 5HT2A receptor inhibitor, sarpogralate hydrochloride, in ischemic canine heart. 
Methods: After hemodynamic stabilization, blood flow of the left anterior descending cor- 
onary artery (LAD) was reduced to one-third of the baseline with low constant coronary 
perfusion pressure (CPP: 40.2±3.4mmHg). Thereafter, sarpogrelate (4.66 mg/CBF (L/ 
rain)) was infused for 15 min into the LAD with or without an intracoronary infusion of L- 
NAME (an inhibitor of NO synthesis; 10 mg/CBF (IJmin)) or GR55562 (a selective 5HTIB 
blocker; 0.457 mg/CBF (LJmin)) (the Sarpogralata+L-NAME group, the Sarpogrelate 
group and the Sarpogrelate+GR55562 group, respectively) under constant CPP. 
Results: There were no significant differences in CBF and CPP at the baseline condition 
between two groups. Fifteen min after the Sarpogralate administration, CBF increased 
from 34.0±4.0 to 44.5±4.4 ml/1OOg myocardium/min (n=10, p<0.01), greater (p<0.05) 
than that in the Sarpogrelate+L-NAME group (from 31.1±3.5 to 31.6±2.7 ml/100g myo- 
cardiurn/min, n=9, N.S.). 
Conclusion: We conclude that a selective serotonin 5HT2A receptor blocker, sarpogre- 
late hydrochloride, increases coronary blood flow during ischemia via nitric oxide-depen- 
dent mechanism in canine hearts. Sarpogralate hydrochloride can be beneficial for the 
treatment of ischemic heart disease. 
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1074-31 Left  Ventr icu lar  Fi l l ing and Remodeling After Myocardial 
Infarction: Results From the GISSI-3 Echo Substudy 
Pier L. Temeorelli. Pantaleo Giannuzzi, Francesco Gentile, Donata Lucci, Aide P. 
Maggioni, Gian Luigi Nicolosi, Sa/vatore Maugeri Foundation, Veruno, Italy, Centre Studi 
ANMCO, Firenze, Italy. 
Background. We sought to determine the relation between LV filling pattern and remodel- 
ing in a large cohort of post-AMI patients (pts). 
Methods. Doppler mitral profile, end-diastolic (EDVi) and end-systolic (ESVi) volume 
index, ejection fraction (EF) and extent of wall motion abnormalities (%WMA) were eval- 
uated in 571 pts enrolled in the GISSI-3 Echo substudy, with echo-Doppler recordings at 
24-48 hours (baseline), pre-discharge, and 6 months after uncomplicated AMI. On trans- 
mitral pattern, peak early (El and late (A) velocity, their ratio (E/A), and early deceleration 
time (DT) were considered. According to baseline DT, pts were assigned to group 1, with 
DT <130 ms (n = 147), and group 2, with DT >130 ms (n = 424). 
Results. Pts in group 1 had greater ESVi (p<0.05) and %WMA (p<0.01), and ]ower EF 
(p<0.008) than those in group 2; moreover, despite a greater increase in DT (from 116 to 
165 ms, group 1; from 173 to 186 ms, group 2, p< 0.001), they showed a more severe 
dilation after 6 months (EDVi: from 61 to 94 mVm2 in group 1; from 78 to 82 ml/m2 in 
group 2, p<0.00t; ESVi: from 46 to 55 ml/m2 in group 1; from 41 to 43 ml/m2 in group 2, 
p<0.001) together with an impairment in EF (from 44 to 42%, group 1; from 48 to 46% 
group 2, p< 0.008) and a lesser recovery of %WMA (from 31 to 28 group 1; from 23 to 17 
group 2, p<0.01). Among the 147 group 1 pts, those with pre-discharge persistent DT 
<130 ms (n = 56) showed at 5 months a greater EDVi and ESVi enlargement (p<0.001), 
and a greater impairment in EF (p<0.009) compared to those (n = 91) with significant pro- 
longation of DT (>130 ms). At multivariate analysis, baseline DT <130 ms (OR: 2.38), 
EDVi (OR: 0.96) and %WMA (OR: 1.02) were predictors of >5% dilation at 6 months; 
moreover, when changes in %WMA, EF and DT from baseline to pre-discharge were 
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included in the analysis, baseline %WMA (OR: 1.02) and EDVi (OR: 0.95), together with 
pre-discharge persistent short (<130 ms) DT (OR: 3.06), predicted severe (>20%) late LV 
dilation. 
Conclusion. LV dilation occurs even in uncomplicated MI, in spite of significant recovery 
of %WMA and improvement in LV filling. A short (<130 ms) baseline DT which persists at 
pre-discharge allows identification of pts more compromised and at high risk for progres- 
sive late LV dilation. 
1074-32 Benef ic ia l  Effect of  Revascular izsUon in E lder ly Pat ients  
With Card iogen ic  Shock 
Aaron Kuoetmass. Sai Sadanandan, Lynn G. Tarkington, Salvatora L Battaglia, Apdl W. 
Simon, Steven D. Culler, Edmund R. Becker, Emory Universi~ Atlanta, Georgia, 
University of Oklahoma, Oklahoma City, Oklahoma. 
Background: Previous studies of cardiogenic shock (CS) patients have shown patients 
_> 75 y/o (older CS) do not receive benefit from coronary revascularization. This retro- 
spective study assesses the impact of various revascularization treatment strategies on 
in-hospital survival rates among CS patients in a community setting, after adjusting for 
differences in a patient's gender and 27 co-morbid conditions, 
Method: The sample for this study, 5,030 consecutive CS patients who had a hospital- 
ization with a primary diagnosis of acute MI, was selected from a dataset on all patients 
discharged from HCA Hospitals for the period January 1998 through March 2001. Logis- 
tic regression analysis, estimated separately for younger (n=2525) and old (n=2505) CS 
patients, was used to determine if the observed revascularization treatment strategy 
(thrombolytic only, PCI only, CABG only, or PCI and CABG) improved hospital survival. 
Results: The table indicates that elderly CS patients undergoing revescularization treat- 
ment are between 1.73 times (thrombolytics only) and 2.49 times (CABG only) more 
likely to survive an acute MI hospitalization than elderly CS patient receiving no treat- 
ment. Younger CS patients received even greater benefit from each treatment strategy. 
Conclusions: Reperfusion with thrombolytics or mechanical revascularization signifi- 
cantly impoves survival in older, as well as younger AMt patients with CS. An aggressive 
revascularization strategy should be considered in elderly CS patients. 
Risk Adjusted Odds Ratios for Survival by Treatment Strategy Relative to No 
Treatment 
Age < 75 Age 75 or Greater 
Thrombotytics Only 1.93 (p=0.007) 1.73 (p=0.033) 
PCI Only 2.39 (p<O.O01) 2.06 (p<0.001) 
CABG Only 2.61 (p<O.001) 2.49 (p<O.001) 
PCI and CABG 3.01 (p<O.001) 2.47 (p=O.O06) 
1074-33 Improving Outcome in Treatment of Diabet ics With ST 
Elevation Myocardial Infarction: Insights From the 
GUSTO Trials 
Hitinder S. G~rm, WH Wilson Tang, David Lee, Gang Jia, A Michael Lincoff, Eric J. Topoi, 
Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Diabetics with acute ST-segment elevation myocardial infarction (MI) have 
a worse outcome compared to non-diabetics. Higher risk patients are more likely to ben- 
efit from advances in medical therapy. Methods: We analyzed the diabetic patients 
enrolled in GUSTO I, III and V trials to define the trends in use of adjuvant therapies and 
in short-term outcome. We excluded patients from countries that were not represented in 
all the three trials. Results: The GUSTO I,III and V trials enrolled 9200 diabetics and 
52,509 non-diabetics. Compared with non-diabetics, diabetics were more likely to be 
older (mean age 63.98 ± 10.68 vs. 60.77 ± 12.19, P < 0.001), female (35.1% vs. 24.3%, 
P <0.001), and more likely to have previous history of CHF, CABG, MI, previous PTCA, 
hypertension and greater body weight. Diabetics were at a greater risk of in-hospital 
death (9.5% vs. 5.5% %, P <0.001), and 30 day mortality (10.4% vs 6.0, P < 0.001 ). Con- 
clusions: Compared to non-diabetics, diabetics continue to have a worse presentation 
and a worse outcome with myocardial infarction. Compared to patients enrolled in 
GUSTO I and III, patients enrolled in GUSTO V were more likely to receive beta blockers 
and angiotensin converting enzyme inhibitors and to have a better 30 day survival. This 
improved outcome is predominantly due to an improved survival of patients in Killip class 
I and II. 
Diabetic subset GUSTO I GUSTO Ill GUSTO V P value 
Number 14.5% 15.7% 16.4% 0.001 
(Diabetic/Total) (5376/37110) (1886/11996) (1938/12603) 
30 day mortality 10.7% 10.9% 8.9% 0.061 
30 day-mortality (Killip I and II) 9.3% 9.6% 7.5% 0.04 
(474/5 f 19) (173/1802) (140/1870) 
30 day mortality (Killip lit and IV) 44.5% 44.1% 50.0% 0.722 
(89/200) (26/59) (32/64) 
ACE inhibitor use 28.9% 54.9% 67.3% <0.001 
Beta blocker use 75.1% 75.7% 83.5% <0.001 
Aspirin use 98.1% 98.6% 93.2% <0.001 
